Kura Oncology

Aging Populations And Precision Medicine Will Widen Oncology Frontiers

AnalystHighTarget

Not Invested

Consensus Narrative from 11 Analysts

Published

07 Aug 25

Updated

21 Aug 25

AnalystHighTarget's Fair Value

US$40.00

80.9% undervalued

21 Aug

US$7.65

-62.1%

4.2%

Author's Valuation

US$40.0

80.9% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$40.0

80.9% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

43.23%

Biotech revenue growth rate

11.97%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.78%

Calculation

US$360.22m

Earnings '28

16.32x

PE Ratio '28

US$5.88b

Market Cap '28

US$5.88b

Market Cap '28

120.70m

No. shares '28

US$48.70

Share Price '28

US$48.70 Share Price '28

Discounted to 2025 @ 6.78% p.a.

US$40.00

Fair Value '25